AbbVie Inc. (ABBV) Balances Analyst Caution with Pipeline Progress and Long-Term Growth

Core Viewpoint - AbbVie Inc. is considered one of the best healthcare stocks to buy for 2026, with Goldman Sachs reaffirming a Neutral rating and a price target of $223 ahead of its Q4 2025 earnings and 2026 guidance release [1] Financial Performance - Goldman Sachs projects AbbVie will achieve $67.1 billion in revenue for 2026, with $21.3 billion from Skyrizi and $10.4 billion from Rinvoq, alongside an EPS of $14.22, which aligns with consensus expectations [1] - A slight revenue beat is anticipated in Q4, driven by Skyrizi's performance exceeding expectations, while Rinvoq is expected to perform slightly below [2] Business Segments - The Aesthetics business is under continued pressure, while Neurology and Oncology are expected to show steady results [2] - AbbVie has a high P/E ratio of 168.95, reflecting strong growth expectations, supported by a dividend yield of 3.09% [2] Clinical Trials - AbbVie reported mixed results in the phase 3 Lymphoma trial for epcoritamab, showing improved progression-free survival but failing to meet the overall survival endpoint [3] - The adverse events observed were consistent with the known safety profile of the candidate drug [3] Strategic Response - AbbVie and its partner Genmab are investigating potential factors that may have negatively influenced the trial results, including the impact of the COVID-19 pandemic and the availability of new anti-lymphoma therapies [4] Company Overview - AbbVie is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for complex health issues, specializing in immunology, oncology, neuroscience, and eye care [5]